EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment

• Published in: Nature communications Vol. 13; no. 1; pp. 3535 - 21
• Main Authors: Bhatia, Shilpa, Nguyen, Diemmy, Darragh, Laurel B., Van Court, Benjamin, Sharma, Jaspreet, Knitz, Michael W., Piper, Miles, Bukkapatnam, Sanjana, Gadwa, Jacob, Bickett, Thomas E., Bhuvane, Shiv, Corbo, Sophia, Wu, Brian, Lee, Yichien, Fujita, Mayumi, Joshi, Molishree, Heasley, Lynn E., Ferris, Robert L., Rodriguez, Olga, Albanese, Christopher, Kapoor, Mohit, Pasquale, Elena B., Karam, Sana D.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 20.06.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 13/106; 13/109; 13/31; 13/44; 13/51; 14/34; 38; 38/1; 45/77; 45/90; 45/91; 631/67; 631/67/1536; 64; 64/60; 692/4028/67/1536; Angiogenesis; Animals; Antagonists; Cancer; Drug development; EphA4 protein; Ephrin-B2 - genetics; Genetic engineering; Head & neck cancer; Head and neck carcinoma; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - genetics; Humanities and Social Sciences; Immunoregulation; Lymphocytes T; Mice; multidisciplinary; Receptor, EphB4 - genetics; Receptors; Science; Science (multidisciplinary); Squamous cell carcinoma; Squamous Cell Carcinoma of Head and Neck - drug therapy; Squamous Cell Carcinoma of Head and Neck - genetics; Tumor Microenvironment; Tumor suppressor genes
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-022-31124-7

Differential outcomes of EphB4-ephrinB2 signaling offers formidable challenge for the development of cancer therapeutics. Here, we interrogate the effects of targeting EphB4 and ephrinB2 in head and neck squamous cell carcinoma (HNSCC) and within its microenvironment using genetically engineered mice, recombinant constructs, pharmacologic agonists and antagonists. We observe that manipulating the EphB4 intracellular domain on cancer cells accelerates tumor growth and angiogenesis. EphB4 cancer cell loss also triggers compensatory upregulation of EphA4 and T regulatory cells (Tregs) influx and their targeting results in reversal of accelerated tumor growth mediated by EphB4 knockdown. EphrinB2 knockout on cancer cells and vasculature, on the other hand, results in maximal tumor reduction and vascular normalization. We report that EphB4 agonism provides no additional anti-tumoral benefit in the absence of ephrinB2. These results identify ephrinB2 as a tumor promoter and its receptor, EphB4, as a tumor suppressor in HNSCC, presenting opportunities for rational drug design. EphrinB2 and its receptor EphB4 are highly expressed in head and neck squamous cell carcinoma (HNSCC) and disrupting EphB4-ephrinB2 interaction generates sub-optimal outcomes. Here, compartmental targeting of EphB4 and ephrinB2 in HNSCC cancer cell and endothelial compartments suggests that ephrinB2 acts as a tumor promoter and EphB4 as a tumor suppressor.